Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Iovance Biotherapeutics Inc

Healthcare US IOVA

3.79USD
-0.31(7.56%)

Last update at 2026-06-03T20:29:00Z

Day Range

3.774.12
LowHigh

52 Week Range

3.2118.33
LowHigh

Fundamentals

  • Previous Close 4.10
  • Market Cap2789.94M
  • Volume9132787
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-451.03200M
  • Revenue TTM1.90M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Minority interest - - - - -
Net income -389.92300M -327.82100M -257.22500M -187.07100M -123.58000M
Selling general administrative 104.10M 83.66M 60.21M 40.85M 28.43M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 21.14M 13.98M 1.14M 1.17M 0.96M
Ebit -420.01300M -356.68300M -261.93700M -208.04100M -129.21400M
Ebitda -398.87800M -342.70300M -260.79700M -206.87200M -128.25800M
Depreciation and amortization 21.14M 13.98M 1.14M 1.17M 0.96M
Non operating income net other - 0.45M 2.36M 9.32M 4.68M
Operating income -398.87800M -342.70300M -261.93700M -206.87200M -128.25800M
Other operating expenses 398.88M 342.70M 261.94M 206.87M 128.26M
Interest expense 2.98M 0.45M 2.36M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 2.98M 0.45M - 9.32M 4.68M
Net interest income 2.98M 0.45M 2.36M 9.32M 4.68M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.97000M -14.43100M -2.35600M -10.48500M 4.68M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 398.88M 342.70M 261.94M 206.87M 128.26M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.98M 0.45M 2.36M 9.32M 4.68M
Discontinued operations - - - - -
Net income from continuing ops -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Net income applicable to common shares -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 780.35M 663.98M 777.33M 768.46M 344.65M
Intangible assets 229.26M - - - -
Earning assets - - - - -
Other current assets 17.46M 7.27M 3.55M 6.66M 9.41M
Total liab 195.74M 164.34M 155.67M 111.96M 45.68M
Total stockholder equity 584.61M 499.64M 621.66M 656.50M 298.97M
Deferred long term liab - - - - -
Other current liab 69.41M 52.30M 56.77M 35.07M 16.27M
Common stock 0.01M 0.00800M 0.00700M 0.00600M 0.00500M
Capital stock 0.01M 0.01M 0.01000M 0.01000M 0.00900M
Retained earnings -2012.37500M -1568.33800M -1172.44500M -830.19300M -570.61200M
Other liab - - - 11.71M 2.35M
Good will - - - - -
Other assets - 185.71M 777.33M 73.20M 8.93M
Cash 114.89M 231.73M 78.23M 67.33M 13.97M
Cash and equivalents - - - - -
Total current liabilities 110.31M 91.48M 89.20M 54.87M 39.08M
Current deferred revenue 0.00000M - - - -
Net debt -39.02600M -147.28500M -6.69800M -15.67000M -2.46900M
Short term debt 7.78M 12.59M 5.06M 6.28M 7.25M
Short long term debt - - - - -
Short long term debt total 75.86M 84.45M 71.53M 51.66M 11.50M
Other stockholder equity 2594.45M 2068.87M 1794.69M 1486.66M 869.35M
Property plant equipment - 178.25M 100.94M 59.16M 8.54M
Total current assets 307.85M 471.85M 507.96M 636.10M 312.53M
Long term investments - 0.00000M 91.59M - -
Net tangible assets - 499.63M 621.66M 656.49M 298.97M
Short term investments 164.98M 240.11M 426.18M 562.11M 293.11M
Net receivables 0.15M - - - -
Long term debt 1.00M 1.00M 1.00M - -
Inventory 10.37M - - - -
Accounts payable 33.12M 26.60M 27.38M 13.51M 15.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.53M -0.90200M -0.60100M 0.02M 0.22M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00600M 0.00500M
Preferred stock total equity - - 0.00300M 0.00400M 0.00400M
Retained earnings total equity - - -1172.44500M -830.19300M -570.61200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.27M -171.81700M 7.87M 18.44M 12.89M
Deferred long term asset charges - - - - -
Non current assets total 472.50M 6.43M 269.38M 132.36M 32.12M
Capital lease obligations 74.86M 84.45M 70.53M 51.66M 11.50M
Long term debt total - - 1.00M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 256.45M 37.71M -271.06200M 96.94M -385.08100M
Change to liabilities 5.88M 27.66M 21.14M 19.43M 4.74M
Total cashflows from investing activities 256.45M 0.13M -317.85300M 90.03M -386.27900M
Net borrowings - 1.00M 1.00M 1.00M 1.00M
Total cash from financing activities 190.15M 239.27M 576.42M 6.13M 424.31M
Change to operating activities -8.77500M 17.58M 5.95M -2.69800M 1.16M
Net income -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Change in cash 153.85M 11.46M 53.44M -62.73300M -63.22100M
Begin period cash flow 84.31M 72.85M 19.42M 82.15M 145.37M
End period cash flow 238.16M 84.31M 72.85M 19.42M 82.15M
Total cash from operating activities -292.75700M -227.94100M -205.13400M -158.88900M -101.24900M
Issuance of capital stock 189.50M 203.16M 567.04M - 398.82M
Depreciation 21.14M 13.98M 1.14M 1.17M 0.96M
Other cashflows from investing activities - - - 96.94M -385.08100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 1.66M 1.59M 576.71M 6.44M 424.53M
Other cashflows from financing activities -1.00700M 34.53M 9.38M 6.13M 25.49M
Change to netincome 84.89M 69.77M 40.89M 23.96M 20.04M
Capital expenditures 20.43M 37.57M 46.79M 6.92M 1.20M
Change receivables - - - - -
Cash flows other operating - 7.76M -10.59000M -2.47200M -2.06500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 11.46M 53.44M -62.73300M -63.22100M
Change in working capital -2.89200M 24.55M 2.98M 10.01M 2.67M
Stock based compensation 84.02M 69.77M 40.89M 24.28M 20.03M
Other non cash items 0.87M 6.01M 7.57M 6.62M -1.32300M
Free cash flow -313.18200M -265.51500M -251.92500M -165.80600M -102.44700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IOVA
Iovance Biotherapeutics Inc		 -0.31 7.56% 3.79 - - 2903.48 5.90 2730.73 -7.5961
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Inc

825 Industrial Road, San Carlos, CA, United States, 94070

Key Executives

Name Title Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, Pres, Gen. Counsel & Corp. Sec. 1974
Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer 1972
Dr. Igor P. Bilinsky Chief Operating Officer 1973
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 1967
Ms. Sara Pellegrino VP of Investor Relations & PR NA
Ms. Tracy Winton Sr. VP of HR NA
Mr. Howard B. Johnson M.B.A. Chief Bus. Officer 1960
Mr. James Ziegler M.B.A. Exec. VP of Commercial NA
Mr. Madan Jagasia Exec. VP of Medical Affairs NA
Dr. Raj K. Puri M.D., Ph.D. Exec. VP of Regulatory Strategy & Translational Medicine NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions